HVEM Protein, Human, Recombinant (His Tag): Product Information
> 90 % as determined by SDS-PAGE
< 1.0 EU per μg of the protein as determined by the LAL method
Measured by its binding ability in a functional ELISA. Immobilized recombinant Human HVEM-His(Cat:10334-H08H) at 10 μg/ml (100 μl/well) can bind human BTLA-Fc (Cat:11895-H02H) with a linear range of 1.28-20 μg/ml.
A DNA sequence encoding the extracellular domain (Met 1-Val 202) of human HVEM (NP_003811.2) was expressed, fused with a C-terminal polyhistidine tag.
The secreted recombinant human HVEM consists of 177 amino acids and predicts a molecular mass of 19 kDa. By SDS-PAGE under reducing conditions, the apparent molecular mass of rhHVEM is approximately 33-38 kDa due to glycosylation.
Lyophilized from sterile PBS, pH 7.4 1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. 2. Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Measured by its binding ability in a functional ELISA.
Immobilized recombinant Human HVEM-His(Cat:10334-H08H) at 10 μg/ml (100 μl/well) can bind human BTLA-Fc (Cat:11895-H02H) with a linear range of 1.28-20 μg/ml.
HVEM Protein, Human, Recombinant (His Tag): Alternative Names
Herpesvirus entry mediator (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a member of type I transmembrane protein belonging to the TNF-receptor superfamily. It is expressed on many immune cells, including T and B cells, NK cells, monocytes, and neutrophils. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. However, recent studies have revealed that HVEM is also involved in the unique inhibitory signaling pathway for T cells through activating tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) in B and T lymphocyte attenuator (BTLA). HVEM provides a stimulatory signal following engagement with LIGHT (TNFSF14) on T cells. In contrast, it can also provide an inhibitory signal to T cells when it binds the B and T lymphocyte attenuator (BTLA), a ligand member of the Immunoglobulin (Ig) superfamily. Thus, HVEM may be viewed as a molecular switch, capable of facilitating both stimulatory and inhibitory cosignaling in T cells. Substantial evidence from both human disease and from experimental mouse models has indicated that dysregulation of the LIGHT-HVEM-BTLA cosignaling pathway can cause inflammation in the lung and in mucosal tissues.
Successfully added to cart Please enter catalog numberSubmitted successfullyNetwork ErrorPlease enter your company namePlease enter your namePlease enter your emailPlease enter a valid email addressPlease enter some message